12:00 AM
Feb 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pagoclone: Phase IIb start

This quarter, Indevus will begin a double-blind, placebo-controlled, U.S. Phase llb trial, with an open-label extension, in about 300 patients. Teva, which has...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >